CytomX Therapeutics, Inc. (CTMX)

In the past six months, CytomX Therapeutics' stock price was significantly impacted by several events. Positive Phase 1 clinical data for Varsetatug Masetecan led to a 48.72% premarket stock increase. A public offering of common stock and warrants raised approximately $234.4 million. Multiple financial analysts revised their ratings and increased their price targets for CytomX Therapeutics. The company reported its Q4 and full year 2025 financial results, posting an EPS of -$0.22 for Q4 2025, missing analysts' expectations. CytomX reported its third-quarter 2025 financial results, including $6.0 million in revenue and $143.6 million in cash and investments.

As a clinical-stage biopharmaceutical company, CytomX Therapeutics, Inc. does not generate revenue from product sales. Its revenue primarily stems from collaboration agreements, milestone payments, and potential future capital raises. The company's financial performance is more influenced by clinical trial progress, regulatory milestones, partnership agreements, and overall investor sentiment rather than seasonal consumer patterns.

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing innovative cancer therapies. The company uses its Probody® therapeutic platform to create targeted cancer treatments activated in the tumor microenvironment, minimizing harm to healthy tissues. Key product candidates include Varsetatug Masetecan, CX-2029, CX-904, and CX-801. CytomX collaborates with pharmaceutical companies like AbbVie, Amgen, and Moderna to develop and commercialize its Probody® therapeutics.

CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. While its primary operations are in the U.S., its collaborations suggest a broader international reach for therapy development and commercialization.

CytomX Therapeutics' brand reputation has been significantly influenced by its clinical trial progress and financial activities. Positive Phase 1 data for Varseta-M in colorectal cancer led to favorable analyst sentiment and increased price targets. The company faces inherent risks, including dependence on its PROBODY® therapeutic technology platform and reliance on collaboration revenue. Insider selling activity by company executives could be perceived negatively by some. Recent positive clinical data has largely contributed to a strengthened reputation.

CytomX Therapeutics, Inc. has significant institutional ownership. Institutional shareholders own approximately 85.02% of the stock, insiders hold about 13.04%, and retail investors own 1.94%. Major institutional owners include Fmr Llc, VR Adviser, LLC, and Perceptive Advisors Llc. Kevin P. Starr is the largest individual shareholder, owning 5.20 million shares, representing 3.07% of the company.